All In Biotech

Drug Trial Radar · NCT00297232

Natalizumab (Tysabri) Re-Initiation of Dosing

An Open-Label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of Natalizumab Following Re-Initiation of Dosing in Multiple Sclerosis Subjects Who Have Completed Study C-1801, C-1802, C-1803, or C-1808 and a Dosing Suspension Safety Evaluation

Last checked: Nov 20, 2026Latest source record: Jul 15, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

1,094

Actual

Start

Mar 2006

Primary completion

Apr 2014

Study completion Apr 2014

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
First posted
Feb 28, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objectives for the initial treatment period of this study are to further evaluate the safety of natalizumab monotherapy by evaluating the risk of hypersensitivity reactions and immunogenicity following re-exposure to natalizumab and confirming the safety of switching from interferon (IFN), glatiramer acetate, or other multiple sclerosis (MS) therapies to natalizumab. The primary objective for the long-term treatment period of this study is to evaluate the long-term impact of natalizumab monotherapy on the progression of disability measured by Expanded Disability Status Scale (EDSS) changes over time.

Conditions

  • Relapsing-Remitting Multiple Sclerosis

Interventions

  • NatalizumabDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to 24-week Confirmed Expanded Disability Status Scale (EDSS) ProgressionTime frame: up to 480 weeks
  2. Time to 48-week Confirmed EDSS ProgressionTime frame: up to 480 weeks
  3. Time to 24-week Confirmed EDSS Improvement Where Baseline ≥ 2.0Time frame: Up to 480 weeks

Locations

112 sites in 21 countries. Site status is shown where the registry gives one.

  • Research Site

    Camperdown, Australia

  • Research Site

    Heidelberg, Australia

  • Research Site

    Parkville, Australia

  • Research Site

    Bruges, Belgium

  • Research Site

    Brussels, Belgium

  • Research Site

    Charleroi, Belgium

  • Research Site

    Diepenbeek, Belgium

  • Research Site

    Melsbroek, Belgium

  • Research Site

    Sijsele, Belgium

  • Research Site

    Vancouver, British Columbia, Canada

  • Research Site

    Halifax, Nova Scotia, Canada

  • Research Site

    Kingston, Ontario, Canada

  • Research Site

    London, Ontario, Canada

  • Research Site

    New York, Ontario, Canada

  • Research Site

    Ottawa, Ontario, Canada

  • Research Site

    Toronto, Ontario, Canada

  • Research Site

    Gatineau, Quebec, Canada

  • Research Site

    Greenfield Park, Quebec, Canada

  • Research Site

    Montreal, Quebec, Canada

  • Research Site

    Brno, Czechia

  • Research Site

    Brno, Czechia

  • Research Site

    Hradec Králové, Czechia

  • Research Site

    Olomouc, Czechia

  • Research Site

    Ostrava, Czechia

  • Research Site

    Pardubice, Czechia

  • Research Site

    Pilsen, Czechia

  • Research Site

    Prague, Czechia

  • Research Site

    Prague, Czechia

  • Research Site

    Aarhus C, Denmark

  • Research Site

    Copenhagen, Denmark

  • Research Site

    Esbjerg, Denmark

  • Research Site

    Helsinki, Finland

  • Research Site

    Tampere, Finland

  • Research Site

    Turku, Finland

  • Research Site

    Besançon, France

  • Research Site

    Bordeaux, France

  • Research Site

    Clermont-Ferrand, France

  • Research Site

    Créteil, France

  • Research Site

    Dijon, France

  • Research Site

    Lille, France

Showing 40 of 112 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.